Precision BioSciences Inc (NASDAQ:DTIL) — Market Cap & Net Worth
Market Cap & Net Worth: Precision BioSciences Inc (DTIL)
Precision BioSciences Inc (NASDAQ:DTIL) has a market capitalization of $184.10 Million ($184.10 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16949 globally and #4020 in its home market, demonstrating a -8.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Precision BioSciences Inc's stock price $6.67 by its total outstanding shares 27601554 (27.60 Million). Also see DTIL total assets for a full breakdown of the balance sheet.
Precision BioSciences Inc Market Cap History: 2019 to 2026
Precision BioSciences Inc's market capitalization history from 2019 to 2026. Data shows change from $11.50 Billion to $184.10 Million (-44.19% CAGR). Also see Precision BioSciences Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Precision BioSciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #467 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1674 of 3165 |
Weight: Precision BioSciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Precision BioSciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Precision BioSciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check DTIL share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.35x
Precision BioSciences Inc's market cap is 3.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $11.50 Billion | $22.24 Million | -$92.88 Million | 517.20x | N/A |
| 2020 | $6.91 Billion | $24.29 Million | -$109.01 Million | 284.37x | N/A |
| 2021 | $6.13 Billion | $115.53 Million | -$30.60 Million | 53.04x | N/A |
| 2022 | $985.38 Million | $25.10 Million | -$111.64 Million | 39.26x | N/A |
| 2023 | $302.24 Million | $48.73 Million | -$61.32 Million | 6.20x | N/A |
| 2024 | $105.16 Million | $68.70 Million | $7.17 Million | 1.53x | 14.67x |
| 2025 | $114.82 Million | $34.26 Million | -$45.72 Million | 3.35x | N/A |
Competitor Companies of DTIL by Market Capitalization
Companies near Precision BioSciences Inc in the global market cap rankings as of September 18, 2026. Review Precision BioSciences Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Precision BioSciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Precision BioSciences Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Precision BioSciences Inc's market cap moved from $11.50 Billion to $ 184.10 Million, with a yearly change of -44.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $184.10 Million | +60.34% |
| 2025 | $114.82 Million | +9.19% |
| 2024 | $105.16 Million | -65.21% |
| 2023 | $302.24 Million | -69.33% |
| 2022 | $985.38 Million | -83.92% |
| 2021 | $6.13 Billion | -11.27% |
| 2020 | $6.91 Billion | -39.96% |
| 2019 | $11.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Precision BioSciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $184.10 Million USD |
| MoneyControl | $184.10 Million USD |
| MarketWatch | $184.10 Million USD |
| marketcap.company | $184.10 Million USD |
| Reuters | $184.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more